First Presentation of OS Data From Phase 3 KEYNOTE-394 Trial at ASCO GI 2022 KEYNOTE-394 Is One of Seven Clinical Trials in Merck’s Global Development Program in HCC KENILWORTH, N.J., January 18, 2022...
网页链接First Presentation of OS Data From Phase 3 KEYNOTE-394 Trial at ASCO GI 2022 KEYNOTE-394 Is One of Seven Clinical Trials in Merck’s Global Development Program in HCC KENILWORTH, N.J., January 18, 2022...
网页链接
精彩评论